As a leader in the field of antibody research and development, Creative Biolabs is committed to providing the most comprehensive bi-specific antibody (bsAb) antibody services for our global clients. Attracted by the distinctive advantages of bsAb and non-IgG antibodies (mainly IgA, IgM, and IgE), scientists at Creative Biolabs have been trying their best to develop potential bi-specific non-IgG antibodies in recent years.
Our Service
At Creative Biolabs, we are committed to providing the most comprehensive and highest-quality bi-specific antibody services to our global clients. Leveraging our expertise in antibody engineering, we focus on the development of bi-specific non-IgG antibodies, utilizing advanced techniques to optimize their therapeutic potential.
Our services cover every aspect of bi-specific non-IgG antibody development, from initial design to final production. Starting with the design phase, our experts assist with target binding, isotype selection, and mode-of-action determination, followed by optimization to enhance antibody properties such as half-life, size, and stability. Utilizing cutting-edge technologies such as recombinant DNA, hybrid-hybridoma, isotype conversion, and conjugation, we offer scalable solutions to meet both academic and commercial needs.
Our comprehensive service includes:
1. Design and Optimization
We work closely with you to design bsAbs tailored to your specific needs, optimizing for target specificity, binding affinity, and functional performance.
2. Production and Scale-Up
We support production at all scales, utilizing advanced recombinant DNA and hybrid-hybridoma technologies to produce high-quality bi-specific antibodies in the quantities required for your research or commercial endeavors.
3. Custom Solutions
Our team provides personalized service to create bespoke bi-specific non-IgG antibodies that meet the unique requirements of your project.
Highlights
-
Leading Expertise in Bi-Specific Antibodies
Creative Biolabs stands at the forefront of bi-specific antibody research and development. We offer a comprehensive range of services that cover the entire antibody development pipeline, from conceptual design to large-scale production, ensuring high-quality, innovative solutions for diverse therapeutic needs. -
Pioneering Development of Non-IgG Bi-Specific Antibodies
We specialize in the development of non-IgG bi-specific antibodies, such as IgA, IgM, and IgE, which offer unique advantages in immune responses. These antibodies can be leveraged for specialized applications like mucosal immunity and complement activation, paving the way for innovative treatments that traditional IgG-based bsAbs cannot address. -
Versatile Array of BsAb Formats
We offer a broad selection of bi-specific antibody formats, including bispecific single-domain antibodies, diabodies, bispecific Fabs, and other innovative designs. These formats can be customized to suit specific therapeutic goals, providing flexibility in addressing a wide range of diseases and conditions. -
Advanced Technologies for Antibody Optimization
Our optimization process involves advanced technologies like recombinant DNA, hybrid-hybridoma, isotype conversion, and conjugation, which allow us to fine-tune antibody properties such as binding affinity, stability, size, and half-life. This ensures the antibodies perform optimally in complex biological environments, improving both efficacy and manufacturability. -
Scalable Production and Cost Efficiency
Creative Biolabs offers highly scalable production solutions, allowing for a seamless transition from small-scale laboratory research to large-scale manufacturing. Our efficient production platforms, combined with advanced technologies, ensure cost-effective solutions without compromising quality.
Background
Bi-specific antibodies are a class of specialized antibodies capable of simultaneously binding to two different targets - these could be antigens, epitopes, ligands, receptors, or even cells. BsAbs come in a variety of structural formats (e.g., bispecific single-domain antibodies, diabodies, and bispecific Fabs), which are generally categorized into two classes: IgG-like (those with an Fc region) and non-IgG-like (those lacking an Fc region). The latter group, comprising antibodies like IgA, IgM, and IgE, offers distinct advantages such as mucosal immunity and complement activation. These non-IgG BsAbs are poised for use in a variety of applications, including diagnostics, prophylaxis, drug delivery, and most notably, cancer therapy. While several IgG-based bsAbs have been approved for clinical anti-tumor treatments, non-IgG-based bsAbs have yet to be fully explored in clinical settings, making them a promising area for innovation.
Fig. 1 MAb and BsAb structures.1
FAQs
Q1: What is the difference between IgG and non-IgG bi-specific antibodies?
A: IgG bi-specific antibodies contain an Fc region (the tail portion of the antibody), while non-IgG bi-specific antibodies (such as IgA, IgM, and IgE) lack this Fc region. Non-IgG antibodies offer unique properties such as enhanced mucosal immunity and complement activation, which can provide advantages in certain therapeutic applications, including cancer immunotherapy and autoimmune disease treatment.
Q2: How are bi-specific antibodies designed?
A: Bi-specific antibodies are designed by selecting two distinct binding regions that can target two different antigens or epitopes. The design process includes considerations such as isotype selection (IgG-like or non-IgG-like), the mode of action (e.g., immune cell activation, tumor targeting), and optimizing the stability and affinity of the antibody for its targets.
Q3: What are the key challenges in developing non-IgG bi-specific antibodies?
A: One of the main challenges in developing non-IgG bi-specific antibodies is optimizing the stability, size, and half-life of the antibodies, as well as ensuring that they can be produced in large quantities. Additionally, balancing the dual-target binding ability with functional properties like immunogenicity and cytotoxicity can be complex, requiring careful design and testing.
Q4: Can Creative Biolabs assist with both academic and commercial projects?
A: Yes, Creative Biolabs offers tailored solutions for both academic and commercial projects. Whether you are conducting basic research, developing preclinical candidates, or moving into clinical trials, we provide flexible and scalable antibody development services that meet the specific needs of each phase of your project.
Q5: How do I start a project with Creative Biolabs?
A: To begin a project, simply contact our team with details about your specific requirements, including the targets, desired outcomes, and any technical specifications you have in mind. Our scientists will work with you to design and develop a customized bi-specific non-IgG antibody that meets your needs, providing you with a clear timeline and cost estimate for the project.
Resource
Along with years of rich experience in offering innovative and sophisticated bsAb development services to meet customers' exact needs, Creative Biolabs is now confident in offering customized bi-specific non-IgG antibodies and related services. Please do not hesitate to contact us for more details.
Quotation and Ordering
Our customer service representatives are available 24/7/365. You may contact us anytime for assistance. Orders can be placed online, over the phone, by email, or by fax.
Reference
- Golay, Josée, and Alain E. Andrea. "Combined anti-cancer strategies based on anti-checkpoint inhibitor antibodies." Antibodies 9.2 (2020): 17. Distributed under the Open Access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.